CT08761185 LIMITED
Company number 08761185 · Monitor this company
This analysis was written by an AI from the company's public filings. It may contain errors or omissions and is not financial or professional advice.
Strategic Assessment: CT08761185 Limited (formerly Smart Medical Clinics Limited)
1. Executive Summary
CT08761185 Limited—formerly Smart Medical Clinics Limited—is a business in terminal decline that has entered formal liquidation following a catastrophic erosion of shareholder value. The company's net asset position deteriorated from a positive £877k in FY2021 to negative £331k by FY2025, representing a £1.2 million destruction of equity over four years. The recent rebranding to a generic company number designation, mass director resignations, and transition to "non-trading" status confirm this entity has ceased to operate as a viable going concern.
2. Strategic Assets
Minimal Residual Value Remains
-
Intangible Asset—Brand & Regulatory Positioning: The "Smart Medical Clinics" name previously carried positioning value in the private healthcare market; however, the deliberate abandonment of this brand (May 2026 rename) signals any remaining goodwill has been written off or transferred.
-
Debtor Book (£1.0M): The single largest asset on the balance sheet is "other debtors" at £1,007,399—up 11% from the prior year. This concentration in a single asset class is concerning and likely represents intercompany balances or related-party receivables rather than trade debtors, given the company's non-trading status. Collectibility must be scrutinised during liquidation.
-
Cash Position (£96k): Cash declined from £107k to £96k year-on-year despite minimal operations (7 employees vs. 25 the prior year), suggesting ongoing cash burn from administrative costs and creditor servicing.
-
Fixed Assets—Fully Depreciated: Plant and machinery of £2.02M cost basis is now fully depreciated with £0 net book value, eliminating any tangible asset recovery option for creditors.
Assessment: There are no meaningful strategic moats or competitive advantages remaining. The asset base is illiquid and of questionable recoverable value.
3. Growth Opportunities
None Viable—Company is in Liquidation
The company's current status eliminates conventional growth analysis. However, for stakeholders seeking value recovery:
-
Debtor Collection: If the £1M debtor book contains legitimate third-party receivables, aggressive collection could improve creditor recovery rates. This represents the only near-term "upside" scenario.
-
Asset Sale Potential: While fixed assets are fully depreciated, the underlying medical equipment may hold residual market value not reflected on the balance sheet. A liquidator should commission independent valuations.
-
Regulatory Licences: If the company held CQC registration or other healthcare operating licences, these may have transferable value to a purchaser—though the brand abandonment suggests this has been explored and likely exhausted.
Realistic Outlook: Any "growth" narrative is academic. The company is being wound down.
4. Strategic Risks
Critical Threats
| Risk Category | Detail | Severity |
|---|---|---|
| Insolvency | Net liabilities of £331k; shareholders' funds of -£451k. Technically insolvent and in liquidation. | Terminal |
| Secured Creditor Priority | Barclays Bank holds a fixed and floating charge over all property and undertakings, meaning unsecured creditors (including the £444k tax liability) are subordinated and face significant recovery risk. | Critical |
| Debtor Quality | £1M in "other debtors" (not trade debtors) raises material doubt about collectibility. If these are intercompany balances from related entities also in distress, expected losses could be substantial. | Critical |
| Operational Collapse | Headcount reduced from 25 to 7; both directors resigned in April 2026; SIC code changed to "non-trading." The business has ceased operations. | Confirmed |
| Tax Liability Exposure | £444k owed in taxation and social security suggests potential HMRC exposure, which may trigger preferential creditor claims in liquidation proceedings. | High |
| Related Party Complexity | Corporate Holding Group LLC (owning >75%) alongside the Barnes family interests creates potential for transactions that may not maximise returns for other creditor classes. Liquidator must scrutinise intercompany flows. | High |
Financial Trajectory Analysis
The five-year decline is instructive:
FY2021: Net Assets +£877k ← Peak
FY2022: Net Assets +£77k ← £800k erosion (likely asset write-downs/debt crystallisation)
FY2023: Net Assets -£748k ← Insolvency threshold breached
FY2024: Net Assets -£623k ← Marginal improvement (liability restructuring?)
FY2025: Net Assets -£331k ← Further improvement, but still deeply insolvent
While the net liability position improved by approximately £292k between FY2023 and FY2025, this was driven by liability reduction rather than trading performance—likely through debt forgiveness, intercompany settlement, or asset realisations.
Stakeholder Implications
For Creditors: Recovery depends entirely on the quality of the £1M debtor book. If those receivables are realisable, partial recovery may be achievable. If they're impaired intercompany balances, expect significant haircuts.
For Shareholders: With shareholders' funds at -£451k, equity holders are deeply out of the money and will receive nothing in liquidation.
For the Liquidator: Priority actions should include: (1) independent verification of the £1M debtor book collectibility, (2) investigation of the FY2021-to-FY2022 value destruction for potential wrongful trading or preference claims, and (3) review of related-party transactions with Corporate Holding Group LLC.